Clinical Trials Logo
  1. Home
  2. Hematological Diseases
  3. NCT06281496

AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation — AlloCare  

Hematological Diseases Clinical Trial

Official title:
AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation

Clinical Trial Summary

A developed multimodal intervention targeting late effects in survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) will be evaluated in a two-arm randomized controlled trial with an internal pilot phase.

Clinical Trial Description

The study aims to investigate the effect of a multidisciplinary multimodal intervention in allo-HSCT survivors on survivorship-specific health-related quality of life and late effects. Method: This study is designed as a one-site, two-arm prospective randomized controlled trial proceeding an internal pilot phase. Population/recruitment: Recruitment, inclusion, and exclusion criteria as described in the eligibility section. Included patients will be randomized and allocated 1:1 to an intervention group or a control group. Intervention: The intervention is multi-modal and multidisciplinary and consists of two main components including individual consultations based on Patient Reported Outcome Data (HM PRO) and web-based digital health support and education. The multidisciplinary team will consist of nurses, hematologists, physiotherapists, social workers, and dietitians. Data Collection: Patient reported Outcome data will be distributed electronically to patients via Redcap and collected at baseline T1, 6 months from allo-HSCT. Post-intervention data collection T2, 12 months from allo-HSCT, and follow-up assessment T3 at 18 months from allo-HSCT. Primary outcome; Changes in Self-reported HRQoL and burden of late effects measured by EORTC-QOL-SURV100. Secondary outcome: Degree of health literacy measured by the Health Literacy Questionnaire (HLQ). Occurrence of Chronic Graft Versus Host Disease measured by Lee Chronic Graft Versus Host Disease Symptom scale ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06281496
Study type Interventional
Source Rigshospitalet, Denmark
Contact Mette Schaufuss Engedal, MSc
Phone +45 51896699
Email mette.schaufuss.engedal@regionh.dk
Status Not yet recruiting
Phase N/A
Start date May 1, 2024
Completion date December 1, 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02240992 - MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment Phase 2/Phase 3
Recruiting NCT02241031 - Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia Phase 2/Phase 3
Completed NCT02483325 - Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases Phase 2
Recruiting NCT05041933 - Secure Outsourcing of Carfilzomib in the Treatment of Multiple Myeloma to the Hospital at Home Setting
Completed NCT00675038 - Pilot Study of Non-Invasive Assessment of Hepatic And Myocardial Iron Through T2* Magnet Resonance Imaging (MRI) In Patients With Iron Overload N/A
Active, not recruiting NCT03745287 - A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease Phase 2/Phase 3
Recruiting NCT05505760 - Testing Content Delivery Models for MomConnect N/A
Recruiting NCT01160952 - Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation Phase 2
Recruiting NCT00884364 - Exercise During Chemotherapy for Patients With Hematological Malignancies Phase 3
Completed NCT00892502 - Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? N/A
Active, not recruiting NCT00838643 - Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) N/A
Recruiting NCT05329649 - Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) Phase 3
Completed NCT02661035 - Allo HSCT Using RIC for Hematological Diseases Phase 2
Enrolling by invitation NCT06277479 - Late Effects and HRQoL in Survivors of Allo-HSCT - a Cross Sectional Study
Completed NCT00956358 - Study on Systemic and Airway Biomarkers in Haemopoietic Stem Cell Transplantation N/A
Completed NCT01344681 - Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases Phase 2
Recruiting NCT02083731 - MSC for Treatment of CMV Infection Phase 2
Recruiting NCT02083718 - Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function Phase 2
Recruiting NCT01763086 - Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant Phase 2
Recruiting NCT01763099 - Mesenchymal Stem Cells Combined With Cord Blood for Treatment of Graft Failure Phase 2